NM_000492.4:c.2464G>T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000492.4(CFTR):c.2464G>T(p.Glu822*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000492.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.2464G>T | p.Glu822* | stop_gained | Exon 14 of 27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000524 AC: 1AN: 190750Hom.: 0 AF XY: 0.00000980 AC XY: 1AN XY: 102030
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1387646Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 685652
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:3
- -
This sequence change creates a premature translational stop signal (p.Glu822*) in the CFTR gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CFTR are known to be pathogenic (PMID: 1695717, 7691345, 9725922). This variant is present in population databases (rs397508378, gnomAD 0.001%). This premature translational stop signal has been observed in individuals with cystic fibrosis (PMID: 9003508, 11810271, 31523618). ClinVar contains an entry for this variant (Variation ID: 53492). For these reasons, this variant has been classified as Pathogenic. -
The p.E822* pathogenic mutation (also known as c.2464G>T), located in coding exon 14 of the CFTR gene, results from a G to T substitution at nucleotide position 2464. This changes the amino acid from a glutamic acid to a stop codon within coding exon 14. This mutation was first described in a Greek cohort (reported as E822X) in which 8/250 cystic fibrosis patients were found to harbor this mutation; seven had a second alteration described, phase not reported (Tzetis M, Hum. Genet. 1997 Jan; 99(1):121-5). In one study, a severe reduction in mRNA levels in the nasal epithelial cells from patients with this mutation, as compared to controls, was reported (Tzetis M, Hum. Genet. 2001 Dec; 109(6):592-601). This pathogenic mutation is associated with elevated sweat chloride levels, decreased lung function, pancreatic insufficiency, and Pseudomonas infection (Sosnay PR, Nat. Genet. 2013 Oct; 45(10):1160-7, Supplementary Table and The Clinical and Functional Translation of CFTR (CFTR2); available at http://cftr2.org. Accessed November 4, 2015). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Cystic fibrosis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation Pathogenic:1
- -
CFTR-related disorder Pathogenic:1
- -
not provided Pathogenic:1
CFTR: PM3:Very Strong, PVS1, PM2 -
Cystic fibrosis;C0238339:Hereditary pancreatitis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation;C2749757:Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
- -
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at